<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34120226</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>411</StartPage><EndPage>426</EndPage><MedlinePgn>411-426</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10651-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is increasingly recognised as a multi-system disorder, presenting with common and impactful non-motor symptoms, such as neuropsychiatric&#xa0;symtpoms, cognitive and behavioural changes, pain, disordered sleep, fatigue&#xa0;and problematic saliva.</AbstractText><AbstractText Label="AIM/HYPOTHESIS" NlmCategory="OBJECTIVE">We aimed to systematically review 25&#xa0;years of ALS&#xa0;clinical trials data to identify if non-motor features were evaluated, in addition to the traditional measures of motor functioning and survival, and where evaluated to describe the instruments used to assess. We hypothesised that assessment of non-motor symptoms has been largely neglected in trial design and not evaluated with ALS-suitable instruments.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed clinical trials of investigative medicinal products in ALS, since the licensing of riluzole in 1994. Trial registry databases including WHO International Trials Registry, European Clinical Trials Register,&#xa0;clinicaltrials.gov, and PubMed were systematically searched for Phase II, III or IV trials registered, completed or published between 01/01/1994 and 16/09/2020. No language restrictions were applied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">237 clinical trials, including over 29,222 participants, were investigated for their use of non-motor outcome measures. These trials evaluated neuropsychiatric symptoms (75, 32%), cognitive impairment (16, 6.8%), behavioural change (34, 14%), pain (55, 23%), sleep disturbances (12, 5%) and fatigue (18, 8%). Problematic saliva was assessed as part of composite ALS-FRS(R) scores in 184 trials (78%) but with no focus on this as an isolated symptom. 31 (13%) trials including 3585 participants did not include any assessment of non-motor symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Non-motor symptoms such as neuropsychiatric, cognitive and behavioural changes, pain, disordered sleep, fatigue, and problematic saliva have not been consistently evaluated in trials for people with ALS. Where evaluated, non-symptoms were primarily assessed using instruments and impairment thresholds that are not adapted for people with ALS. Future trials should include non-motor symptom assessments to evaluate the additional potential therapeutic benefit of candidate drugs.</AbstractText><AbstractText Label="PROPSERO REGISTRATION" NlmCategory="UNASSIGNED">CRD42020223648.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beswick</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9843-0778</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4 SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forbes</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4 SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Zack</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4 SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Charis</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8488-037X</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4 SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4 SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neurosciences, Psychology, School of Philosophy, Psychology and Language Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4 SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neurosciences, Psychology, School of Philosophy, Psychology and Language Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4276-639X</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK. Suvankar.Pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4 SB, Scotland, UK. Suvankar.Pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK. Suvankar.Pal@ed.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Non-motor symptoms</Keyword><Keyword MajorTopicYN="N">Outcome measures</Keyword></KeywordList><CoiStatement>Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>13</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34120226</ArticleId><ArticleId IdType="pmc">PMC8738361</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10651-1</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10651-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fang T, Jozsa F, Al-Chalabi A. Nonmotor symptoms in amyotrophic lateral sclerosis: a systematic review. Int Rev Neurobiol. 2017;134:1409&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">28805578</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;nther R, et al. Non-motor symptoms in patients suffering from motor neuron diseases. Front Neurol. 2016;7:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958907</ArticleId><ArticleId IdType="pubmed">27504105</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, et al. Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis. J Neurol Sci. 2019;397:92&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">30597420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanner AM, Barry JJ. The impact of mood disorders in neurological diseases: should neurologists be concerned? Epilepsy Behav. 2003;4:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">14592635</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou J-S, et al. Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003;60(1):122&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">12525733</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheja D, et al. Patient-reported problematic symptoms in an ALS treatment trial. Amyotrophic Lateral Scler Frontotemp Degener. 2016;17(3&#x2013;4):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979603</ArticleId><ArticleId IdType="pubmed">26824413</ArticleId></ArticleIdList></Reference><Reference><Citation>Christidi F, et al. Clinical and radiological markers of extra-motor deficits in amyotrophic lateral sclerosis. Front Neurol. 2018;9:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262087</ArticleId><ArticleId IdType="pubmed">30524366</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (2016) Motor neurone disease: assessment and management. [NICE Guideline No. 42]. https://www.nice.org.uk/guidance/ng42</Citation><ArticleIdList><ArticleId IdType="pubmed">26962594</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Berg LH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610&#x2013;e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng L, et al. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;1:1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469543</ArticleId><ArticleId IdType="pubmed">28072907</ArticleId></ArticleIdList></Reference><Reference><Citation>Beswick E, et al. A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. J Neurol. 2020;267:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8563523</ArticleId><ArticleId IdType="pubmed">32910255</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Kliest T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33(5):655&#x2013;661. doi: 10.1097/WCO.0000000000000861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000861</ArticleId><ArticleId IdType="pubmed">32796282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer EM, et al. Validity of the ALS-Depression-Inventory (ADI-12)&#x2014;a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord. 2008;109(1&#x2013;2):213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">18262283</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyotrophic Lateral Scler Frontotemp Degener. 2015;16(3&#x2013;4):172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons CJ, et al. Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health Qual Life Outcomes. 2011;9:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192662</ArticleId><ArticleId IdType="pubmed">21955749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, et al. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale) Eur J Neurol. 2018;25(7):907&#x2013;e66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6005752</ArticleId><ArticleId IdType="pubmed">29577526</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton symptom assessment scale. Cancer. 2000;88(9):2164&#x2013;2171.</Citation><ArticleIdList><ArticleId IdType="pubmed">10813730</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">3395203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, et al. Columbia-suicide severity rating scale (C-SSRS) New York: Columbia University Medical Center; 2008. p. 10.</Citation></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z, et al. The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology. 2006;67(9):1659&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson RF, Brennan C, Crispin MS. Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(1):33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12365067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;6:473&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin R, Charro FD. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11491192</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SR, et al. The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med. 1995;9(3):207&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">7582177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergner M, et al. The sickness impact profile: development and final revision of a health status measure. Medical Care. 1981;8:787&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">7278416</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBSTM) Amyotroph Lateral Scler. 2010;11(3):303&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">20433413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E, et al. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21(11):1078&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">16977673</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, Moore DH, Katz JS. Insight in ALS: awareness of behavioral change in patients with and without FTD. Amyotroph Lateral Scler. 2010;11(1&#x2013;2):52&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19714539</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner P, et al. Help-seeking for dementia: a systematic review of the literature. Alzheimer Dis Assoc Disord. 2014;28(4):299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">25321607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Davidson W, Fox H. Frontal behavioral inventory: diagnostic criteria for frontal lobe dementi. Can J Neurol Sci. 1997;24(1):29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043744</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P, Torny F, Lacoste M. Functional rating scales for amyotrophic lateral sclerosis. Rev Neurol (Paris) 2006;162(4):502&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16585911</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016;86(16):1474&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836879</ArticleId><ArticleId IdType="pubmed">26911633</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">1798888</ArticleId></ArticleIdList></Reference><Reference><Citation>Buysse DJ, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">2748771</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res. 1993;37(7):753&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229906</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z, Felgoise SH, Rodriguez JL, Walsh SM, Bremer BA, Stephens HE. Validation of a shorter ALS-specific quality of life instrument: the ALSSQOL-R. Neurology. 2010;74(suppl 2):A177&#x2013;A178.</Citation></Reference><Reference><Citation>Felgoise SH, et al. Amyotrophic lateral sclerosis&#x2013;specific quality of life&#x2013;short form (ALSSQOL-SF): a brief, reliable, and valid version of the ALSSQOL-R. Muscle Nerve. 2018;58(5):646&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">30028537</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, et al. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol. 1999;246(3):II16&#x2013;II21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10631656</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, et al. Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) Amyotrophic Lateral Scler Frontotemp Degener. 2018;19(1&#x2013;2):65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510059</ArticleId><ArticleId IdType="pubmed">29214872</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(3):131&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12(9):526.</Citation><ArticleIdList><ArticleId IdType="pubmed">27514291</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R, et al. The Parkinson fatigue scale. Parkinsonism Relat Disord. 2005;11(1):49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15619463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri KR, et al. King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pubmed">26096067</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenkwalder C, et al. Parkinson's disease sleep scale&#x2014;validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">21312275</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435.</Citation><ArticleIdList><ArticleId IdType="pubmed">28592904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurt A, et al. Depression and anxiety in individuals with amyotrophic lateral sclerosis. CNS Drugs. 2007;21(4):279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">17381183</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az JL, et al. Effect of a short-term psychological intervention on the anxiety and depression of amyotrophic lateral sclerosis patients. J Health Psychol. 2016;21(7):1426&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pubmed">25370571</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Moraes MH, et al. Suicidal behavior in individuals with amyotrophic lateral sclerosis: a systematic review. J Affect Disord. 2020;277:688&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">32911219</ArticleId></ArticleIdList></Reference><Reference><Citation>McHutchison CA, et al. Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND. J Neurol Neurosurg Psychiatry. 2020;91(3):245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">31871139</ArticleId></ArticleIdList></Reference><Reference><Citation>Benbrika S, et al. Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: a review. Front Neurosci. 2019;13:951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6746914</ArticleId><ArticleId IdType="pubmed">31551700</ArticleId></ArticleIdList></Reference><Reference><Citation>Caga J, et al. The impact of cognitive and behavioral symptoms on ALS patients and their caregivers. Front Neurol. 2019;10:192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421295</ArticleId><ArticleId IdType="pubmed">30915018</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12(4):368&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Radakovic R, et al. Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale. J Neurol Neurosurg Psychiatry. 2016;87(6):663&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">26203157</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. Pain in amyotrophic lateral sclerosis: a population-based controlled study. Eur J Neurol. 2012;19(4):551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">21972798</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksu S, Citak-Karakaya I. Effect of exercise therapy on pain complaints in patients with amyotrophic lateral sclerosis. Pain Clin. 2002;14(4):353&#x2013;359.</Citation></Reference><Reference><Citation>McClelland S, III, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve. 2008;37(3):396&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">17894358</ArticleId></ArticleIdList></Reference><Reference><Citation>Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. Nat Sci Sleep. 2019;11:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701267</ArticleId><ArticleId IdType="pubmed">31496852</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzberg HD, et al. Effects of noninvasive ventilation on sleep outcomes in amyotrophic lateral sclerosis. J Clin Sleep Med. 2013;9(4):345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601313</ArticleId><ArticleId IdType="pubmed">23585750</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Cicolin A. Sleep in ALS: more than discomfort or respiratory breathing disorder. BMJ Publishing Group Ltd.; 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33087418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Coco D, et al. Sleep&#x2013;wake problems in patients with amyotrophic lateral sclerosis: implications for patient management. Neurodegener Dis Manag. 2012;2(3):315&#x2013;324.</Citation></Reference><Reference><Citation>McElhiney M, et al. Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry. 2009;80(10):1146&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons C, Pagnini F, Friede T, Young CA. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2018;1(1):CD011005. doi: 10.1002/14651858.CD011005.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011005.pub2</ArticleId><ArticleId IdType="pmc">PMC6494184</ArticleId><ArticleId IdType="pubmed">29293261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG, et al. Current management of ALS: comparison of the ALS CARE database and the AAN practice parameter. Neurology. 2001;57(3):500&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502920</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson I, Glasmacher SA, Newton J, Beswick E, Mehta AR, Davenport R, Chandran S, Pal S. CARE-MND consortium. The prevalence and management of saliva problems in motor neuron disease: a 4-year analysis of the Scottish motor neuron disease register. Neurodegener Dis. 2020;20(4):147&#x2013;152. doi: 10.1159/000514615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000514615</ArticleId><ArticleId IdType="pmc">PMC7610776</ArticleId><ArticleId IdType="pubmed">33902047</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri A, et al. Quality of life and motor impairment in ALS: Italian validation of ALSAQ. Neurol Res. 2010;32(1):32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092693</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, et al. Translation and psychometric evaluation of a Korean version of the amyotrophic lateral sclerosis-specific quality of life&#x2013;revised. Amyotrophic Lateral Scler Frontotemp Degener. 2017;18(1&#x2013;2):92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">27922756</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvajal A, et al. The Spanish version of the Edmonton Symptom Assessment System-revised (ESAS-r): first psychometric analysis involving patients with advanced cancer. J Pain Symptom Manag. 2013;45(1):129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">22926088</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekala S, et al. Dementia diagnosis in seven languages: the Addenbrooke&#x2019;s Cognitive Examination-III in India. Arch Clin Neuropsychol. 2020;35(5):528&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">32188967</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremolizzo L, Lizio A, Santangelo G, Diamanti S, Lunetta C, Gerardi F, Messina S, La Foresta S, Riva N, Falzone Y, Filippi M, Woolley SC, Sansone VA, Siciliano M, Ferrarese C, Appollonio I. ALS-CBS Italian study group. ALS cognitive behavioral screen (ALS-CBS): normative values for the Italian population and clinical usability. Neurol Sci. 2020;41(4):835&#x2013;841. doi: 10.1007/s10072-019-04154-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04154-1</ArticleId><ArticleId IdType="pubmed">31807998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, et al. Spanish adaptation of the edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS) Amyotrophic Lateral Scler Frontotemp Degener. 2018;19(1&#x2013;2):74&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212378</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, et al. The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS) Amyotrophic Lateral Scler Frontotemp Degener. 2016;17(7&#x2013;8):489&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberici A, et al. The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease. Neurol Sci. 2007;28(2):80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17464470</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda E, et al. Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. No to shinkei. Brain Nerve. 1996;48(11):999&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">8951891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hita-Contreras F, et al. Reliability and validity of the Spanish version of the Pittsburgh Sleep Quality Index (PSQI) in patients with fibromyalgia. Rheumatol Int. 2014;34(7):929&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">24509897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>